Evropská unie - čeština - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vakcíny - profylaxe chřipky způsobené virem a (h1n1) v roce 2009. přípravek celvapan by měl být používán v souladu s oficiálními pokyny.

Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

v.m.d. n.v. - procaine benzylpenicillin, combinations with other antibacterials - intramamární mast - beta-laktamová antibiotika, peniciliny, kombinace s jinými antibakteriálními - krávy v laktaci

Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

vetpharma ah, s.l. - macrolides, combinations with other substances - injekční roztok - makrolidy - skot

Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

zoetis Česká republika s.r.o. (2) - macrolides, combinations with other substances - injekční roztok - makrolidy - skot

Evropská unie - čeština - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anémie, kosáčková buňka - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Evropská unie - čeština - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Evropská unie - čeština - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocytopenická, idiopatická - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 a 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 a 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Evropská unie - čeština - EMA (European Medicines Agency)

nordic group b.v. - tegafur, gimeracil, oteracil - neoplazmy žaludku - antineoplastická činidla - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

linde gas a.s., praha array - 2473 oxid dusnÝ - medicinální plyn, zkapalněný - 100% - oxid dusnÝ

Evropská unie - čeština - EMA (European Medicines Agency)

mylan ireland limited - abirateron acetátu - prostatetické novotvary - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.